Lineage Cell Therapeutics (LCTX) Non Operating Investment Income (2018 - 2021)

Lineage Cell Therapeutics has reported Non Operating Investment Income for 4 years, with the latest figure at $6.0 million in Q1 2021.

• For the quarter ending Q1 2021, Non Operating Investment Income rose 378.86% year-over-year to $6.0 million; the trailing twelve-month figure through Dec 2021 stood at $6.0 million (up 32.11% YoY), and the FY2021 full-year result was $6.0 million, up 32.11% from the prior year.
• Non Operating Investment Income for Q1 2021 stood at $6.0 million, up from $712000.0 in the prior quarter.
• The five-year high for Non Operating Investment Income was $6.0 million in Q1 2021, with the low at -$607000.0 in Q2 2019.
• Historically, Non Operating Investment Income has averaged $1.2 million across 4 years, with a median of $523000.0 in 2018.
• The largest YoY upside for Non Operating Investment Income was 8834.78% in 2019 against a maximum downside of 252.9% in 2019.
• Lineage Cell Therapeutics' Non Operating Investment Income stood at $523000.0 in 2018, then slumped by 54.88% to $236000.0 in 2019, then jumped by 201.69% to $712000.0 in 2020, then soared by 746.07% to $6.0 million in 2021.
• The last three Non Operating Investment Income figures came in at $6.0 million (Q1 2021), $712000.0 (Q4 2020), and $120000.0 (Q3 2020), per Business Quant data.